To overcome immunosuppressive signals, personalized vaccines loaded with patient-derived engineered DCs or delivery of innate stimulus such as TLR3 ligand or a STING agonist to DCs at the tumour site are being developed and have shown promising results (181, 182). Here, STING1 is linked to neoplasm.